Nakata A, Hagita M, Okamoto U
Nihon Seirigaku Zasshi. 1978 Nov;40(11):419-26.
When fibrinolytic activity in blood samples from various vessels was examined by the dilute-blood-clotlysis-time method (DBCLT), it was found to be noticeably high in the renal venous blood, though the activity was not detected by usual blood clotlysis time method. Plasmin was not detected in any blood samples examined, and the contents of fibrinogen and fibrin (or fibrinogen) breakdown products in the renal venous blood were not significantly different from those in the blood from other vessels. However, the high activity of plasminogen-activator was found only in the renal venous blood. Inhibitors on plasmin and plasminogen-activator (urokinase) were detected in almost the same amount in the blood samples from the various vessels. The amount of the inhibitors was sufficient to inhibit the plasminogen activation by urokinase, whose activity was equivalent to the plasminogen-activator activity in the renal venous blood. These results indicate that the high activity by DBCLT in the renal venous blood was derived from the high activity of plasminogen-activator, which was inactivated by inhibitors in undiluted blood. Plasminogen-activator may be released from the kidney to the blood, and immediately inactivated by the inhibitors in renal vein, and then diluted with systemic blood which contains little plasminogen-activator.
当采用稀释血液凝块溶解时间法（DBCLT）检测来自不同血管的血液样本中的纤溶活性时，发现肾静脉血中的纤溶活性明显较高，尽管用常规血液凝块溶解时间法未检测到该活性。在所检测的任何血液样本中均未检测到纤溶酶，并且肾静脉血中纤维蛋白原和纤维蛋白（或纤维蛋白原）降解产物的含量与来自其他血管的血液中的含量无显著差异。然而，仅在肾静脉血中发现了高活性的纤溶酶原激活剂。在来自不同血管的血液样本中检测到的纤溶酶和纤溶酶原激活剂（尿激酶）抑制剂的量几乎相同。抑制剂的量足以抑制尿激酶对纤溶酶原的激活，尿激酶的活性与肾静脉血中的纤溶酶原激活剂活性相当。这些结果表明，肾静脉血中DBCLT检测到的高活性源自纤溶酶原激活剂的高活性，其在未稀释的血液中被抑制剂灭活。纤溶酶原激活剂可能从肾脏释放到血液中，并立即在肾静脉中被抑制剂灭活，然后被几乎不含纤溶酶原激活剂的全身血液稀释。
